SGLT2 inhibitors significantly reduced the risk of HF, frequency of hospitalizations due to HF, all-cause mortality, cardiovascular (CV) mortality, and nonfatal myocardial infarction. The gene discussed is SLC5A2; the disease is myocardial infarction.